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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
omalizumab is a safe and effective treatment for chronic urticaria.
STUDY DESIGN: Review of two randomized controlled studies and one crossover study. All
three studies are published in English between 2008-2011.
DATA SOURCES: Two randomized, double blind, placebo controlled studies and one
crossover study found using PubMed and EBSCOhost.
OUTCOMES MEASURED: Each trial measured the duration, size, number and/or intensity of
wheals. This was done by using the urticaria activity score (UAS). Quality of life was also
measured using Dermatology Life Quality Index (DLQI), Skindex-29, and Chronic Urticaria
Quality of Life Questionnaire (Cu-Q2oL).
RESULTS: The first study, the Maurer et al study showed that after 24 weeks of treatment with
omalizumab, there was a mean change in UAS7 from baseline of -17.8. Saini et al study showed
a mean change in UAS7 from baseline of -19.9 after four weeks of omalizumab treatment.
Quality of life measured in the Maurer et al study showed that those treated with omalizumab
experienced as least a 50% improvement. No serious adverse events were noted in any of the
three studies. Most common adverse events include diarrhea, nasopharyngitis, and headache.
CONCLUSION: Based on these three trails, omalizumab is a safe and effective treatment for
chronic urticaria. Each study showed a significant improvement of symptoms without any
serious side effects when using omalizumab.
KEY WORDS: Omalizumab, Xolair, Urticaria
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INTRODUCTION
Urticaria is a pruritic dermatologic wheal like lesion that can be associated with
angioedema. It is considered chronic, if symptoms persist for more than six weeks. In about half
of patients with chronic urticaria, a cause cannot be identified making it increasingly difficult to
properly treat.1 This paper evaluates two double blind randomized controlled studies and one
crossover study comparing the efficacy of omalizumab compared to a placebo for the treatment
of chronic urticaria.
Chronic urticaria is relevant to the Physician Assistant profession due to its prevalence,
lack of successful treatment options and costs to the patients effected. Chronic urticaria can have
significant effects on patients’ quality of life. Urticaria is extremely common, effecting 15-23%
of the general populations.2 Whereas the incident rate for chronic urticaria is about 0.5%.2 The
annual medical costs per patient is estimated at about $1,725 with medications costing about
$1,280, outpatient visits costing $280, emergency department/hospital visits costing about $148,
and laboratory studies costing about $17 per year per patient.3 Not only do these patients spend a
significant amount of money per year due to chronic urticaria but they also have many health
care visit. The exact number of visits each year is unknown but a study published in January of
2008 in JAMA took 50 patients with chronic urticaria and analyzed them from December 1,
2004 to May 31, 2006. Of the 50 participants, 46 went to visit an outpatient facility and 15 went
to visit the emergency department at least once within this time period.3
For 80% of patients with chronic urticaria, the cause is unknown making it extremely
difficult to find a successful treatment. For the other 20%, chronic urticaria can involve IgG
auto-antibody production against IgE or its receptor (FceRI) leading mast cell degranulation and
subsequently causing symptoms.4,5 Some patients with chronic urticaria can produce IgE
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autoantibodies against thyroperoxidase (TPO).5 As previously stated, in the majority of cases, a
cause cannot be identified but exasperating factors such as stress, alcohol, extreme heat/cold,
NSAIDS, and spicy foods may contribute to an outbreak.2 Due to the unknown etiology, there is
currently no curative treatment.4
In acute urticaria, the treatment of choice is to remove the cause. Because the cause is
usually unknown in terms of chronic urticaria, symptomatic treatment has been the standard of
care.2 Usually, urticaria is treated with antihistamines. If symptoms do not resolve, you can
increase the dose or add another antihistamine.6 If antihistamines are ineffective,
glucocorticoids, immunosuppressive agents, immunomodulatory agents or leukotriene modifying
agents can be used.6 Once symptoms have resolved, patients should stay on the current drug
regimen as maintenance therapy.6
The current recommended drug regimen is many times unsuccessful. Omalizumab
(Xolair) is a humanized anti-IgE monoclonal antibody.1 It is currently being used for the
treatment of IgE mediated asthma but may be of some benefit to those suffering from chronic
urticaria.1 Xolair binds to the C3 area of the IgE heavy chain. The C3 area is where IgE would
essentially bind to FceRI receptor on the target cells (mast cells and basophils).5 By occupying
this site, free IgE levels in the serum will be reduced as well as a down regulation of FceRI
expression leading to a decrease in the release of inflammatory mediators.5
OBJECTIVE
The objective of this systematic review is to determine whether or not omalizumab is a
safe and effective treatment for chronic urticaria.
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METHODS
Three studies were utilized in this review. Two being randomized, double blind, placebo
controlled studies and one crossover study. The population includes patients with symptomatic
chronic urticaria. The intervention used was omalizumab. The dose depends on the patients’
weight and serum IgE levels. The treatment group receiving omalizumab was compared to those
receiving a placebo. Outcomes measured include number and size of hives, adverse events,
pruritis intensity and quality of life.
Keywords used when searching for the articles used consist of omalizumab, xolair, and
urticaria. The articles chosen were researched by the author and obtained through either PubMed
or EBSCOhost. They were selected based on the types of studies and relevance to the clinical
question. All articles chosen are published in English. Inclusion criteria for selecting these
articles included randomized controlled or crossover studies which include outcomes that
directly benefit the patient. Exclusion criteria included patients that experience acute urticaria,
those with other skin conditions, and those successfully being managed with antihistamines,
steroids, or immunosuppresants. The statistics that were utilized and reported include numbers
needed to treat (NNT), numbers needed to harm (NNH), relative risk reduction (RRR), absolute
risk reduction (ARR), relative benefit increase (RBI), absolute benefit increase (ABI), relative
risk increase (RRI), absolute risk increase (ARI) and p-value. Table 1 displays the demographics
and characteristics of the included studies.
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Table 1 - Demographics and Characteristics of included studies
Study
Type
#
Age
Inclusion Criteria
Exclusion
Pts (yrs)
Criteria
Maurer5 Double 49 18-70
(2011)
blind
RCT

Saini1
(2011)

Double 90 12-75
blind
RCT

W/D

Interventions

-Symptoms for >6
weeks despite antihistamine use.
-Body weight
between 20-150 kg.
-IgE level between
30-700 IU/mL.
-IgE-anti-TPO
antibody level >5
IU/mL.
-Weekly UAS >10.

-Acute urticaria 7
-Steroid or
immunosuppressant use
within 4 weeks.
-Hx of epilepsy,
malignancy, or
CVA.
-Increased IgE
levels for other
reasons.

Subcutaneous
Omalizumab
(75-375 mg)
q2-4 wks x 24
wks

-Moderate-severe
chronic urticaria
despite antihistamine use.
-UAS of >4 (clinic),
and >12 (pt diary)

Weight <40 kg. 19

Omalizumab

Omalizumab
within 12
months.

Dose - 75, 300,
and 600 mg

Dose based on
body weight
and IgE levels

Other skin d/o.
Kaplan7 Cross(2008)
over
study

12 18-75

-Symptoms for >6 Physical,
0
weeks despite anti- vasculitis, or
histamine use
urticaria d/t
-IgE <700 IU/mL
secondary
-(+) basophil
reasons.
histamine release OR
autologous skin test Steroid or
-At least moderate immunopruritus (score of >2) suppressant use
-At least moderate within 4 weeks
pruritus, # of hives,
and size (score of
>4).

Placebo for 4
weeks. Then
omalizumab for
16 weeks.
Given q2 or 4
weeks
Dose depends
on weight and
IgE levels

Davis, Chronic Urticaria and Omalizumab 5
OUTCOMES MEASURED
The outcomes measured include duration, size, number and/or intensity of wheals,
pruritus, erythema, and angioedema were done so by using the urticaria activity score (UAS).1,5,7
The UAS is based off patient diaries. Because of the day to day variations of the disease, the
mean weekly UAS (UAS7) ranging from 0-42 was utilized and compared with baseline
scores.1,5,7 Quality of life was also measured using Dermatology Life Quality Index (DLQI),
Skindex-29, and Chronic Urticaria Quality of Life Questionnaire (Cu-Q2oL).5,7 DLQI is a
questionnaire consisting of 10 items under 6 headings (symptoms, daily activities, leisure,
work/school, personal relationships, and treatment). Each item is scored based on
severity/impairment from 0-3 with higher scores meaning more severe impairment.5,7 Skindex29 consists of 29 items in three categories (physical symptoms, social functioning, and emotional
state) with scores ranging from 0-100 combined.5 Cu-Q2oL consists of 23 items with the
following categories: limits, looks, swelling/eating, functioning, sleep, mental status, and
embarrassment.5 Each item is scored based on a five point scale.5
RESULTS
All three articles compared the use of omalizumab with the use of a placebo for the
treatment of chronic urticaria. Mauerer et al and Saini et al are double blind, randomized
controlled trials whereas Kaplan et al study is a crossover study. Each article was presented as
continuous data which then was converted into dichotomous data in order to asses the
improvement in symptoms, adverse reactions, and quality of life.
Maurer et al study excluded those taking steroids, or immunosuppresants within the last
four weeks. Also, those with increased IgE levels for reasons other than chronic urticaria were
excluded as well.5 The UAS7 scores were compared from baseline to week 24 (Table 2). The
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mean change in UAS7 from baseline in the treatment group was -17.8 and the placebo group,
only -7.9. There was a difference of 9.9 points between the treatment and the control group
which is statistically significant (95% CI, P-value=0.0089).5 After 24 weeks of treatment, 67%
of those being treated with omalizumab were completely symptom free whereas only 4% of
those receiving placebo were symptom free according to the investigator’s global assessment
(Table 3).5 Therefore, the NNT was calculated as two (Table 3). This indicates that for every
two patients treated with omalizumab for 24 weeks, one patient will achieve complete resolution
of their symptoms.
Saini et al study excluded those who have taken omalizumab within the last 12 months
and those with other skin conditions. The UAS7 scores were compared at baseline and then
again at week four (Table 2). There was a statistically significant improvement with the P-value
<0.001 in those treated with 300mg of omalizumab compared to those treated with the placebo.
In four weeks, patients in the treatment group had a mean UAS score 19.9 points lower than they
did at baseline (Table 2) and 36% achieved complete resolution of symptoms (Table 3). No
single patient in the placebo group were symptom free after four weeks of treatment (Table 3).
Furthermore, the NNT was calculated as three after converting continuous data into dichotomous
data (Table 3). For every three patients with chronic urticaria that receive 300mg of omalizumab
for four weeks, one patient will have complete resolution of symptoms.
Kaplan et al study is a crossover study where 12 patients with chronic urticaria received a
placebo for four weeks and then omalizumab for 16 weeks. The mean baseline UAS7 score was
7.50 (1.78).7 During the last 4 weeks of omalizumab treatment, the mean UAS7 score was 2.66
(3.31).7 There was a significant mean change from baseline of -4.84 (2.86) with a P-value of
0.0002 during the last four weeks of omalizumab treatment (Table 2). Out of the 12 participants,
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seven of them (58%) achieved complete resolution of symptoms.7 This being said, NNT was
calculated to be two patients (Table 3) meaning that for every two patients treated, one will
achieve complete resolution of symptoms.
Table 2. Efficacy of omalizumab when compared to placebo
Study

Group

Maurer5, 2011

Saini1, 2011

Kaplan7, 2008

Mean (SD) change in UAS7 from
baseline

Omalizumab

-17.8

Placebo

-7.9

Omalizumab

-19.9 (12.38)

Placebo

-6.9 (9.84)

N/A

-4.82 (2.86)

Table 3. Efficacy of treating chronic urticaria with omalizumab
Study

Complete
Resolution of
Symptoms

Relative
Benefit
Increase
(RBI)

Maurer5, 2011

Omalizumab - 67%
Placebo - 4%

15.75

Saini1, 2011

Omalizumab - 36%
Placebo - 0%

Kaplan7, 2008

58%

Absolute
Benefit
Increase
(ABI)

Number
Needed to
Treat (NNT)

P-Value

0.63

2 Patients

N/A

N/A

0.36

3 Patients

<0.001

N/A

N/A

2 Patients

<0.05

Adverse reactions were analyzed by the Maurer et al and the Saini et al study. Maurer et
al study showed that 81.5% of those being treated with omalizumab and 86.4% being treated
with a placebo experienced an adverse reaction with diarrhea, nasopharyngitis, and headache
being some of the most common.5 The NNH was calculated by converting continuous data into
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dichotomous data at -20 (Table 4). Therefore, for every 20 patients treated with omalizumab,
one fewer patient would experience an adverse effect (AE) when compared to placebo.
Saini et al study found that out of the 25 patients receiving 300mg of omalizumab, 12
experienced an adverse event (Table 4).1 Of the 21 patients receiving the placebo, 10 patients
experienced an AE (Table 4).1 After converting the continuous data into dichotomous data, the
NNH is calculated to be 250 patients. Therefore, for every 250 patients treated with 300mg of
omalizumab, one will then experience and adverse reaction.
Table 4. Results and Analysis of Adverse Effects
Study

% experiencing AEs

Relative Risk
Increase (RRI)

Maurer5, 2011

Omalizumab - 81.5% -5.7%
Placebo - 86.4%

Saini1, 2011

Omalizumab - 48%
Placebo - 47.6%

Absolute Risk
Increase (ARI)

-4.9%

0.8%

Number
Needed to
Harm (NNH)
-20

0.4%

250

Quality of life was analyzed in the Maurer et al study. Table 5 shows the percentage of
improvement based off of the three different questionnaires assessing quality of life (DLQI,
Skindex-29, and Cu-Q2oL). Each questionnaire showed that those receiving omalizumab
experienced a greater improvement in quality of life compared to those receiving the placebo.
This is statistically significant for all three questionnaires with a P-value of <0.01.5
Table 5. Improvement in quality of life
Group

DLQI

Skindex-29

Cu-Q2oL

Omalizumab

62.4%

50%

53.2%

Placebo

15.3%

6.3%

5.9%

DISCUSSION
Omalizumab is an IgG monoclonal antibody directed against IgE and is currently only
approved in the United States for the use of moderate-severe allergic asthma in those over the
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age of 12.8 Initially, several case reports and a small series showed that omalizumab may have a
beneficial effect for those with chronic urticaria.6 Because omalizumab is not currently approved
for the use of chronic urticaria, cost may be a barrier preventing patients from utilizing this drug.
Insurance companies reimburse on a “patient by patient basis”.6 Several contraindications and
concerns need to be taken into consideration when using omalizumab. Anaphylaxis is a black
box warning.8 If anaphylaxis occurs, it usually does within the first two hours.8 Delayed onset
anaphylaxis is also possible and can even be seen over a year after the drug regimen was started.8
Contraindications include previous hypersensitivity reaction to omalizumab, acute
bronchospasm, and status asthmaticus.8
All three studies analyzed showed a greater improvement in chronic urticaria with the use
of omalizumab compared to the use of a placebo. This review supports the use of omalizumab in
the treatment of chronic urticaria but there are several limitations in the studies used. In the
Kaplan et al study, the sample size was extremely small with only 12 participants. Even though
the data suggests that omalizumab improves the symptoms of chronic urticaria, the small sample
size may not accurately represent the total population of those effected with this disease. The
larger sample sizes in Maurer et al and Saini et al studies better depict the outcome of treating
chronic urticaria with omalizumab. Another limitation in the Kaplan et al study is that it is a
crossover study and not a double blind randomized controlled study. P-values were not given in
the Maurer et al study when discussing those who had a complete resolution of symptoms
leading to questioning of statistical significance.
CONCLUSION
Based on this systematic review and the chosen studies, omalizumab is a safe an effective
treatment for chronic urticaria. The data within these three studies are consistent with the
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beneficial effects of omalizumab as well as its overall safety. No serious adverse effects were
noted and participants’ quality of life improved. Future studies should include double blind
randomized controlled trials with larger sample sizes. Also, researching the use of omalizumab
as a complementary drug to use along with current drug regimens may show some benefits.
Continued research should include longer durations of treatment to better evaluate the benefits
verses the risks of treating chronic urticaria with omalizumab.
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